Tudriqev (vusolimogene oderparepvec-wtpg)
Antineoplastic-Immunotherapy Virus-Based Agents Injection Vial (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This medication is used in combination with another medication (nivolumab) to treat a certain type of skin cancer (melanoma). It contains a live virus (cold sore virus) that has been weakened. Vusolimogene oderparepvec infects the cancer cells and works by slowing or stopping their growth.
Generic name: vusolimogene oderparepvec-wtpg
Pronunciation: (VUE-soe-LIM-oh-jeen oh-DER-pa-REP-vek)
Drug class: Antineoplastic-Immunotherapy Virus-Based Agents
Therapeutic class: Antineoplastics
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Tudriqev
Indications
The following indications are listed for Tudriqev:
- Malignant Melanoma
Also known as: Melanoblastoma, Melanocarcinoma, Melanoma, Melanosarcoma, Melanotic Carcinoma.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Vusolimogene Oderparepvec/Live Vaccines
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The interaction potential of live virus vaccines with vusolimogene oderparepvec is unknown.
CLINICAL EFFECTS: Concurrent administration of live vaccines with vusolimogene oderparepvec may alter the effectiveness or toxicities of either agent.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of vusolimogene oderparepvec states that vaccines containing live attenuated viruses should be avoided during vusolimogene oderparepvec therapy.(2) Patients should be advised that their cancer gene therapy may be delayed due to administration of vaccines.(3)
DISCUSSION: The concomitant use of live attenuated vaccines and vusolimogene oderparepvec has not been evaluated. The manufacturer's recommendation is based on vaccine guidance used in clinical trials.(2)
There are no severe interactions for this drug.
Moderate Interaction: Assess the risk to the patient and take action as needed.
Vusolimogene Oderparepvec/Non-Live Or Nonreplicating Vaccine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The interaction potential of non-live or non-replicating vaccines with vusolimogene oderparepvec is unknown.
CLINICAL EFFECTS: Concurrent administration of non-live or non-replicating vaccines with vusolimogene oderparepvec may alter the effectiveness or toxicities of either agent.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of vusolimogene oderparepvec states that non-live and non-replicating vaccines should ideally be delayed until the current course of vusolimogene oderparepvec therapy is completed. If vaccination is required during treatment, separate administration of the vaccine and vusolimogene oderparepvec by at least 14 days.(2) Patients should be advised that their cancer gene therapy may be delayed due to administration of vaccines.(3)
DISCUSSION: The concomitant use of non-live or non-replicating vaccines and vusolimogene oderparepvec has not been evaluated. The manufacturer's recommendation is intended to minimize potential interactions and confounding factors in the safety assessments of vaccines and vusolimogene oderparepvec therapy.(2)
Vusolimogene Oderparepvec/Selected Antivirals
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Vusolimogene oderparepvec is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy.(1)
CLINICAL EFFECTS: Administration of antiviral agents with activity against HSV-1 may interfere with the effectiveness of vusolimogene oderparepvec.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Patients receiving systemic antiviral treatment for herpetic infection should delay vusolimogene oderparepvec for 72 hours after completing antiviral therapy.(1)
DISCUSSION: Agents that inhibit herpes simplex virus activity may impair the ability of vusolimogene oderparepvec to replicate in tumors.(1) Antiviral agents with activity against HSV-1 include: acyclovir, cidofovir, famciclovir, foscarnet, ganciclovir, valacyclovir, and valganciclovir.
Contraindications
There is no enhanced messaging for this drug.
- Lactation
- Herpes simplex infection
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Injection site sequelae
Less Frequent
- Acute kidney injury
- Acute myocardial infarction
- Atrial fibrillation
- Atrial flutter
- Enterocolitis
- Hypophysitis
- Multiple organ failure
- Pain
- Pleural effusions
- Pneumothorax
- Sepsis
- Urinary tract infection
Rare or Very Rare
- Capillary leak syndrome
More Frequent
- Acute abdominal pain
- Anemia
- Anorexia
- Arthralgia
- Chills
- Constipation
- Cough
- Diarrhea
- Dizziness
- Dyspnea
- Elevated serum amylase
- Elevated serum lipase
- Fatigue
- Fever
- Flu-like symptoms
- Headache disorder
- Hemorrhage
- Hyperkalemia
- Hypoalbuminemia
- Hypoglycemic disorder
- Hypokalemia
- Hyponatremia
- Hypophosphatemia
- Increased alanine transaminase
- Increased alkaline phosphatase
- Increased aspartate transaminase
- Infection
- Lymphopenia
- Musculoskeletal pain
- Nausea
- Pruritus of skin
- Skin rash
- Vomiting
Less Frequent
- Edema
Rare or Very Rare
- Herpes simplex infection
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Malignant melanoma | ||
| C43 | ICD10CM | Malignant melanoma of skin |
| C43.0 | ICD10CM | Malignant melanoma of lip |
| C43.1 | ICD10CM | Malignant melanoma of eyelid, including canthus |
| C43.10 | ICD10CM | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | ICD10CM | Malignant melanoma of right eyelid, including canthus |
| C43.111 | ICD10CM | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | ICD10CM | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | ICD10CM | Malignant melanoma of left eyelid, including canthus |
| C43.121 | ICD10CM | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | ICD10CM | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | ICD10CM | Malignant melanoma of ear and external auricular canal |
| C43.20 | ICD10CM | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | ICD10CM | Malignant melanoma of right ear and external auricular canal |
| C43.22 | ICD10CM | Malignant melanoma of left ear and external auricular canal |
| C43.3 | ICD10CM | Malignant melanoma of other and unspecified parts of face |
| C43.30 | ICD10CM | Malignant melanoma of unspecified part of face |
| C43.31 | ICD10CM | Malignant melanoma of nose |
| C43.39 | ICD10CM | Malignant melanoma of other parts of face |
| C43.4 | ICD10CM | Malignant melanoma of scalp and neck |
| C43.5 | ICD10CM | Malignant melanoma of trunk |
| C43.51 | ICD10CM | Malignant melanoma of anal skin |
| C43.52 | ICD10CM | Malignant melanoma of skin of breast |
| C43.59 | ICD10CM | Malignant melanoma of other part of trunk |
| C43.6 | ICD10CM | Malignant melanoma of upper limb, including shoulder |
| C43.60 | ICD10CM | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | ICD10CM | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | ICD10CM | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | ICD10CM | Malignant melanoma of lower limb, including hip |
| C43.70 | ICD10CM | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | ICD10CM | Malignant melanoma of right lower limb, including hip |
| C43.72 | ICD10CM | Malignant melanoma of left lower limb, including hip |
| C43.8 | ICD10CM | Malignant melanoma of overlapping sites of skin |
| C43.9 | ICD10CM | Malignant melanoma of skin, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.